SEPTEMBER 2021LIFE SCIENCES REVIEW6The rising chronic diseases and the consequent increase in the demand for innovative therapies have fast-tracked biologic drugs in the market. From cancer, autoimmune diseases, rheumatoid arthritis, to name a few, biologics have successfully offered treatments for many major diseases. But as the drug manufacturers attempt to create new biologic molecules, they need to involve critical analysis to determine dosage, toxicology and efficacy. This is where bioanalytics marks its essence in the process of drug development. Without bioanalytics, vital data points might be missing in drug development, leading to loss of money and time down the line. Bioanalytics also provides crucial information to regulatory bodies that can facilitate in accelerating drug development or even identify harmful drugs quicker, helping researchers to effectively modify the products.One of the foremost reasons supporting the vitality of bioanalytical studies is understanding and identifying the bioanalytical endpoints early on, which impact the design of toxicology studies. In comparison to new chemical entities (NCEs), the timely delivery of nonclinical programs that support first-in-human (FiH) studies for biologics and advanced therapeutics need closer interaction between toxicology and bioanalytical teams--the reason why the study holds immense importance. Besides, bioanalytical studies help define and shape safety studies and decision making. To ensure achieving the best practices, there rises a need to partner with an analyst early and throughout the development pipeline. An appropriate partnership between bioanalysts and drug developers makes it simple to access required analytical platforms and help in the program design, the analyte, the analytical platform, sourcing of reference standards and many more aspects. This not only saves costs and time but speeds up the planning. Further, partnerships offer input and guidance on choices of the technical platform and validation criteria for assays that are outside the regulatory guidance. The careful selection of the right bioanalytical partner is a must to bring significant benefits for an efficient, accurate and accelerated drug development program. Hence, to facilitate industry leaders in taking up the right path in embracing bioanalytical services, the editorial board at Life Science Review has identified the best-in-class service providers in this space.Let us know your thoughts!EDITORIALPartnering with Analysts for Streamlining Therapeutic DevelopmentCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Contact Us:Phone:510-230-0395Fax:510-894-8405Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com September - 17 - 2021, Vol 02, Issue - 08 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald Donovan*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comAsher Blake
< Page 5 | Page 7 >